Recent Updates
Recently added Catalysts
BJDX Positive Sentiment

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Wednesday, June 26, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Bluejay Diagnostics, Inc. announced positive results from the SYMON-I study, which explored the role of interleukin-6 (IL-6) in sepsis patients. The study indicates that IL-6 levels upon ICU admission may help predict mortality risk. This multicenter pilot study adds valuable insights into sepsis management.

Market Sentiment Analysis

POSITIVE FACTORS

  • The study shows promising results for predicting mortality in sepsis patients.
  • IL-6 could be a valuable biomarker for assessing patient outcomes.
  • The multicenter approach enhances the reliability of the findings.

Full Press Release Details

ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the utility of IL-6 upon initial presentation to the intensive care unit (ICU).
More details.

Frequently Asked Questions

What is the SYMON-I study about?

The SYMON-I study investigates the role of interleukin-6 (IL-6) in sepsis patients.

What were the findings of the SYMON-I study?

The study suggests that IL-6 levels can help predict mortality in sepsis patients.

Who conducted the SYMON-I study?

The study was conducted by Bluejay Diagnostics, Inc.

What is the significance of IL-6 in sepsis?

IL-6 may serve as a valuable biomarker for assessing patient outcomes in sepsis.

ShareAdd on Google
Tags: BJDX Viatris Investor Conferences Healthcare IL-6 sepsis mortality clinical study
Last updated: Jun 26, 2024

Biotech snapshot

Cash runway
$10M liquidity · $1M/mo burn
~19 mo
Low dilution risk